GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » Beneish M-Score

Reata Pharmaceuticals (Reata Pharmaceuticals) Beneish M-Score : 34.23 (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 34.23 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Reata Pharmaceuticals's Beneish M-Score or its related term are showing as below:

RETA' s Beneish M-Score Range Over the Past 10 Years
Min: -5.3   Med: -2.49   Max: 34.23
Current: 34.23

During the past 10 years, the highest Beneish M-Score of Reata Pharmaceuticals was 34.23. The lowest was -5.30. And the median was -2.49.


Reata Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Reata Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals Beneish M-Score Chart

Reata Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -2.76 -3.10 -2.44 -4.51

Reata Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.13 -3.07 -4.51 17.75 34.23

Competitive Comparison of Reata Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Reata Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reata Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's Beneish M-Score falls into.



Reata Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Reata Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1.0374+0.404 * 92.5408+0.892 * 2.3481+0.115 * 0.6967
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6406+4.679 * -0.254481-0.327 * 2.0081
=34.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $22.66 Mil.
Revenue was 22.746 + 0.195 + 0 + 0.54 = $23.48 Mil.
Gross Profit was 21.9 + 0.195 + 0 + 0.54 = $22.64 Mil.
Total Current Assets was $401.85 Mil.
Total Assets was $502.59 Mil.
Property, Plant and Equipment(Net PPE) was $89.90 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.13 Mil.
Selling, General, & Admin. Expense(SGA) was $159.87 Mil.
Total Current Liabilities was $125.09 Mil.
Long-Term Debt & Capital Lease Obligation was $163.55 Mil.
Net Income was 192.998 + -116.117 + -85.502 + -79.002 = $-87.62 Mil.
Non Operating Income was 282.174 + 5.355 + -1.065 + 2.149 = $288.61 Mil.
Cash Flow from Operations was -69.928 + -81.449 + -50.426 + -46.534 = $-248.34 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.762 + 0.914 + 0.933 + 7.391 = $10.00 Mil.
Gross Profit was 0.762 + 0.914 + 0.933 + 7.391 = $10.00 Mil.
Total Current Assets was $491.21 Mil.
Total Assets was $631.55 Mil.
Property, Plant and Equipment(Net PPE) was $140.19 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.22 Mil.
Selling, General, & Admin. Expense(SGA) was $106.28 Mil.
Total Current Liabilities was $46.33 Mil.
Long-Term Debt & Capital Lease Obligation was $134.29 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.662 / 23.481) / (0 / 10)
=0.965121 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10 / 10) / (22.635 / 23.481)
=1 / 0.963971
=1.0374

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (401.849 + 89.901) / 502.587) / (1 - (491.21 + 140.192) / 631.549)
=0.021562 / 0.000233
=92.5408

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=23.481 / 10
=2.3481

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.223 / (1.223 + 140.192)) / (1.13 / (1.13 + 89.901))
=0.008648 / 0.012413
=0.6967

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(159.868 / 23.481) / (106.282 / 10)
=6.808398 / 10.6282
=0.6406

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((163.547 + 125.093) / 502.587) / ((134.293 + 46.325) / 631.549)
=0.574309 / 0.285992
=2.0081

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-87.623 - 288.613 - -248.337) / 502.587
=-0.254481

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Reata Pharmaceuticals has a M-score of 34.23 signals that the company is likely to be a manipulator.


Reata Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
5320 Legacy Drive, Plano, TX, USA, 75024
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Executives
Steven Ryder director 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai director, 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni officer: EVP, Chief R&D Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand officer: SVP, Chief Accounting Officer 5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni officer: COO, CFO and President C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir officer: Chief Commercial Officer C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen officer: SVP, Global Regulatory Affairs C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr. director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley officer: See Remarks 5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John officer: See Remarks C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc. other: See footnotes 225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan officer: SVP, Chief Medical Officer 5320 LEGACY DRIVE, PLANO TX 75024

Reata Pharmaceuticals (Reata Pharmaceuticals) Headlines

From GuruFocus